Every 10-Q that Lifemd Inc (LFMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LFMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFMD filings page.
LifeMD, Inc. reported telehealth revenue of $47.3 million for the quarter and $97.4 million for the six months ended June 30, 2026, compared with $49.0 million and $99.9 million a year earlier. Gross profit rose to $86.2 million for the six-month period as cost of telehealth revenue declined.
Higher spending, particularly in selling and marketing, drove total operating expenses to $102.3 million for six months, up from $88.5 million, resulting in an operating loss from continuing operations of $16.1 million. Net loss from continuing operations was $15.96 million, and net loss attributable to common stockholders was $17.51 million (loss per share $0.37 versus $0.08 in 2025), as prior-year results benefited from profitable discontinued operations.
Cash decreased by $11.64 million in six months to $25.1 million, with continuing operations using $6.48 million of operating cash flow. LifeMD has no debt outstanding, an undrawn $30 million revolving credit facility, and $44.6 million remaining under its at-the-market equity program; management expects these resources to cover at least 12 months of planned needs. A covenant breach on an interest coverage ratio as of March 31, 2026 was waived, and new leverage, fixed-charge coverage, and liquidity tests begin with the quarter ending September 30, 2026.
LifeMD, Inc. reported stronger Q3 2025 results, with total revenue rising to $60.2 million from $53.3 million a year earlier, driven by growth in telehealth and steady WorkSimpli software subscriptions. For the first nine months of 2025, revenue reached $187.0 million, up from $149.3 million in the prior-year period, while the operating loss narrowed sharply to $1.4 million from $14.4 million.
Net loss attributable to common stockholders improved to $4.6 million in the quarter and $7.9 million year-to-date, compared with $5.4 million and $18.8 million in the prior-year periods, despite ongoing preferred dividends of $2.3 million for the nine months. LifeMD generated $11.6 million of cash from operations year-to-date, repaid its remaining $14.0 million Avenue credit facility, and ended September 30, 2025 with $23.8 million in cash and positive stockholders’ equity of $3.4 million. Management states that existing cash should fund planned operations and capital needs for at least the next 12 months.